On March 29, 2023,
HC Wainwright & Co.
initiated coverage of Legend Biotech with
a Buy recommendation.
Analyst Price Forecast Suggests 51.50% Upside
As of March 28, 2023,
the average one-year price target for Legend Biotech is $72.93.
The forecasts range from a low of $65.65 to a high of $82.95.
The average price target represents an increase of 51.50% from its latest reported closing price of $48.14.
See our leaderboard of companies with the largest price target upside.
The projected annual revenue for Legend Biotech
is $206MM, an increase of 74.16%.
The projected annual non-GAAP EPS
is -$1.35.
What are Large Shareholders Doing?
Hillhouse Capital Advisors
holds 5,137K shares
representing 3.07% ownership of the company.
No change in the last quarter.
SMCWX – SMALLCAP WORLD FUND INC
holds 3,396K shares
representing 2.03% ownership of the company.
In it’s prior filing, the firm reported owning 4,034K shares, representing
a decrease
of 18.78%.
The firm
decreased
its portfolio allocation in LEGN by 3.72% over the last quarter.
Ra Capital Management
holds 2,436K shares
representing 1.46% ownership of the company.
In it’s prior filing, the firm reported owning 2,339K shares, representing
an increase
of 4.01%.
The firm
increased
its portfolio allocation in LEGN by 21.17% over the last quarter.
Capital World Investors
holds 2,390K shares
representing 1.43% ownership of the company.
In it’s prior filing, the firm reported owning 2,389K shares, representing
an increase
of 0.01%.
The firm
increased
its portfolio allocation in LEGN by 16.19% over the last quarter.
Federated Hermes
holds 2,339K shares
representing 1.40% ownership of the company.
No change in the last quarter.
What is the Fund Sentiment?
There are 357 funds or institutions reporting positions in Legend Biotech.
This is an increase
of
12
owner(s) or 3.48% in the last quarter.
Average portfolio weight of all funds dedicated to LEGN is 0.39%,
an increase
of 12.90%.
Total shares owned by institutions increased
in the last three months by 0.46% to 75,146K shares.
The put/call ratio of LEGN is 0.40, indicating a
bullish
outlook.
Legend Biotech Background Information
(This description is provided by the company.)
Legend Biotech is a global clinical-stage biopharmaceutical company engaged in the discovery and development of novel cell therapies for oncology and other indications. The team of over 800 employees across the United States, China and Europe, along with its differentiated technology, global development, and manufacturing strategies and expertise, provide us with the strong potential to discover, develop, and manufacture cutting edge cell therapies for patients in need.
This story originally appeared on Fintel.
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.
